FAST FACTS
FOUNDER(S):
Dr. Colleen Brophy
Lokesh Joshi
Dr. Alyssa Panitch
INNOVATION(S):
Biotechnology/Pharmaceuticals
HEADQUARTERS:
Tempe, AZ
FOUNDED:
2004
TSC MEMBER INSTITUTION(S):
Arizona State University
FUNDING AGENCY(S):
National Institutes of Health
STATUS:
Acquired
ACQUIRING COMPANY:
Capstone Therapeutics
|
AZERX, INC.
ABOUT THE COMPANY:
Arizona Engineered Therapeutics Inc. (AzERx), a new company based on the research of three Arizona State University (ASU) professors, was formed in May 2004 to develop a drug that would be beneficial to people who have suffered a specific type of stroke induced by a subarachnoid hemorrhage in the brain. In February 2006, the company was acquired by OrthoLogic, Inc., a biotechnology company committed to developing a pipeline of novel therapeutic peptides and other molecules aimed at helping patients with under-served medical conditions. (OrthoLogic is today known as Capstone Therapeutics.)
UNIVERSITY-BASED RESEARCH CONNECTION:
The primary compound of AzERx is based on the research of Dr. Colleen Brophy, director of the Center for Protein and Peptide Therapeutics at Arizona State University’s Biodesign Institute, and Lokesh Joshi, an associate professor and Dr. Alyssa Panitch, an assistant professor, both in the Harrington Department of Bioengineering of the Ira A. Fulton School of Engineering. Their AZX100 is a novel synthetic pre-clinical 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary disease, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Capstone has an exclusive worldwide license to AZX100.
ROLE OF FEDERAL RESEARCH FUNDING:
AZX100 was discovered at ASU with funding from the National Institutes of Health.
 Read The Full Report Here
|
Printer-Friendly Version
ARIZONA ENGINEERED THERAPEUTICS, INC.